Protein Inhibitors STAT3
Project co-financed by the European Union from the European Regional Development Fund under Measure 1.2: Sectoral R & D programs for the Intelligent Development Program 2014-2020. Contract No .: POIR.01.02.00-00-0036 / 15. Project co-funded by the National Center for Research and Development under the Innomed program.
Financing the project from the EU: 9 999 355,06 zł
STAT3 Inhibitors OF PROTEIN
GLG Pharma realizes the project pn. Development of targeted therapy for triple negative breast cancer (TNBC) based on innovative STAT-3 inhibitors such as GLG-805 or GLG-302 and the development of diagnostic tests based on immunochemical methods for rapid TNBC tumor diagnosis due to the presence of activated STAT- 3, as well as attempts to monitor protein concentrations in response to therapy with GLG-805 or GLG-302 molecules. " The TNBC project received in 2016 a grant from the INNOMED program, implemented by the National Research and Development Center under Measure 1.2: R & D Sectoral Operational Programs Intelligent Development 2014-2020 co-financed by the European Regional Development Fund. The value of the entire TNBC Project is PLN 13,586,612.76, of which PLN 9,999,355.07 will be financed by funds from the National Center for Research and Development, which accounts for approximately 74% of eligible costs. The project will be implemented in cooperation with subcontractors from leading Polish universities, research institutes and contract manufacturers.
The TNBC Project aims to develop a Triple Negative Breast Cancer (TNBC) targeted therapy based on the use of innovative GLG-805 or GLG-302 molecules.
The TNBC Project is planned to:
The research will be conducted on the basis of Good Clinical Practice (GCP) principles and based on European legal and regulatory standards and ethical principles. The new generation of therapies will be based on STAT-3 protein inhibitors, unique and small molecules that block the action of STAT-3 protein in cells, resulting in inhibition of uncontrolled growth of tumor cells. Therapy provides new treatment options with an alternative chemotherapy mechanism of action. The in vivo and in vitro studies in animal models have demonstrated the high efficiency of GLG Pharma molecules, by their ability to inhibit the growth of cancer cells, decrease tumors and prevent cancer.
In addition, STAT-3 inhibitors will also help to improve the effectiveness of chemotherapy and other targeted therapies by preventing and treating the acquired cancer cell resistance to oncological therapy. Commercialization of research results will take place in Poland. The results of industrial and development research will be widely disseminated through participation in national and international conferences and through publications in scientific journals.
We invite you to familiarize yourself with the inquiry request for the services provided under the project "Development of targeted therapy for triple negative breast cancer based on innovative STAT-3 protein inhibitors, ie GLG-805 or GLG-302, and development of diagnostic tests based on methods Immunochemistry for rapid TNBC tumor diagnosis due to the presence of activated STAT-3 protein, as well as attempts to monitor protein concentration in response to therapy with GLG-805 or GLG-302 molecules "under Action 1.2: Sectoral R & D programs for the Intelligent Development Program 2014 -2020 co-financed by the European Regional Development Fund
USAGE OF GLP-805 TOXICOLOGICAL, TOXICINAL AND GLUC-INFECTION ACTIVE ANIMALS ON THE ANIMAL MODEL
FULL SERVICE OF THE LABORATORY DIAGNOSTICS MANAGER'S FUNCTIONS WITHIN THE R & D WORK
USING THE SYNTHESIS OF THE ACTIVE SUBSTANCE GLG - 805
SERVICE OF CONSTRUCTION OF THE PROJECT WEBSITE AND DESIGN OF PROMOTION MATERIALS
SERVICE OF FULL ROLE OF THE PRESIDENT OF PRESCRIPTION EXAMINATION UNDER R & D WORK
GLG Pharma S.A.
ul. Leszczyńskiego 4 lok. 25
Tel. (+48) 71 758 09 79
Fax. (+48) 71 750 35 50